

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Consultation

- | | |
|------|--|
| 1. | Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
| N/A. | |

- | | |
|--|---|
| 2. | Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
| Expert statements highlighted that that people from ethnic minority backgrounds are less likely to find a fully matched unrelated donor for allogeneic stem cell transplant (ASCT). It was also noted that geographical access to chimeric antigen receptor (CAR) T-cell therapy specialist centres can be a barrier for people in lower socioeconomic groups. The committee noted these concerns but concluded that a technology appraisal cannot change how suitable matches for ASCT are identified and that ASCT was not a direct comparator, so these concerns cannot be addressed within the recommendation. | |

- | | |
|----|---|
| 3. | Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|----|---|

None identified.

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

It is not anticipated that the preliminary recommendation will make it more difficult in practice for a specific group to access the technology. It was raised that there can be difficulties in travelling to CAR T centres, but this is not anticipated to differentially affect groups with protected characteristics.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

None identified.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?

N/A.

7. Have the committee's considerations of equality issues been described in the appraisal consultation document, and, if so, where?

Equalities are discussed in section 3.25 of the draft guidance.

Approved by Associate Director (name): Lorna Dunning

Date: 04/06/2025

Final appraisal determination

(when draft guidance issued)

8.	Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?
	The committee acknowledged the equalities issue around age, noting that a different CAR T-cell treatment is available for people aged under 26 years and that there is an unmet need for people aged 26 years and over. The committee considered if making a recommendation limited to age would affect some people over others. It concluded that there was higher unmet need in those aged 26 years and older who cannot have a CAR T-cell therapy as part of routine practice.
9.	If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
	N/A
10.	If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
	N/A
11.	If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia

3 of 4

Issue date: November 2025

identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?
N/A

12. Have the committee's considerations of equality issues been described in the final appraisal determination, and, if so, where?
Yes, section 3.29

Approved by Associate Director (name): ...Lorna Dunning.....

Date: 18 / 11 / 25